Neuronetics (NASDAQ:STIM – Get Free Report) and Curaleaf (OTCMKTS:CURLF – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.
Volatility & Risk
Neuronetics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Curaleaf has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
Profitability
This table compares Neuronetics and Curaleaf’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuronetics | -19.62% | -125.11% | -22.15% |
| Curaleaf | -2.62% | -0.88% | -0.26% |
Valuation & Earnings
This table compares Neuronetics and Curaleaf”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuronetics | $149.16 million | 1.15 | -$39.00 million | ($0.44) | -5.11 |
| Curaleaf | $1.27 billion | 1.52 | -$231.07 million | ($0.13) | -63.62 |
Neuronetics has higher earnings, but lower revenue than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for Neuronetics and Curaleaf, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuronetics | 1 | 0 | 4 | 0 | 2.60 |
| Curaleaf | 0 | 1 | 2 | 1 | 3.00 |
Neuronetics currently has a consensus price target of $4.67, indicating a potential upside of 107.41%. Curaleaf has a consensus price target of $6.00, indicating a potential downside of 27.45%. Given Neuronetics’ higher probable upside, research analysts clearly believe Neuronetics is more favorable than Curaleaf.
Institutional and Insider Ownership
53.6% of Neuronetics shares are held by institutional investors. Comparatively, 0.0% of Curaleaf shares are held by institutional investors. 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Curaleaf beats Neuronetics on 9 of the 15 factors compared between the two stocks.
About Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
About Curaleaf
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
